Tirzepatide reduces CVD risk biomarkers in T2D


A study in the journal Diabetes, Obesity and Metabolism found that patients with type 2 diabetes who took tirzepatide experienced decrease in biomarkers related to cardiovascular risk, compared with patients treated with dulaglutide or a placebo.

Full story:

DiabetesPro SmartBrief

Diabetes Treatment News

Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals.